Medeor Therapeutics Stock

medeortx.comBioTechFounded: 2012Funding to Date: $67.55MM

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Register for Details

For more details on financing and valuation for Medeor Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Steven Deitcher MD
Co-Founder, Chief Executive Officer, President and Board Member
Matthew Plunkett Ph.D
Chief Financial and Business Officer
Samuel Strober MD
Scientific Founder
Elizabeth Read MD
Senior Vice President, Product Development
Iqbal Husain Ph.D
Senior Vice President, Program Management
Darin Weber Ph.D
Senior Vice President, Regulatory Affairs & Quality
Michael Zdanowski
Vice President, Biopharmaceutical Operations
D. Scott Batty MD
Chief Medical Officer

Board Members

Anand Mehra MD
Sofinnova Investments
Frank Kung Ph.D
Vivo Capital
Peter Kolchinsky Ph.D
RA Capital Management
Steven Deitcher MD
Wei Li Ph.D
WuXi Healthcare Ventures

Other companies like Medeor Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$197.73MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM